Expression and identification of type 1 diabetes associated autoantigen IA-2

Objectives To obtain prokaryotic expressed IA-2 recombinant protein and to identify its immunological activity.Methods The complimentary DNA (cDNA) coding for the intracytoplasmic part of IA-2 (IA-2ic) was amplified from human fetal brain RNA, and was subcloned into the PinPoint Xa-1 T vector to con...

Full description

Saved in:
Bibliographic Details
Published inChinese medical journal Vol. 116; no. 4; pp. 524 - 528
Main Author 周文中 郑升 谢晓雁 杨键 李纪平 罗敏 贾秀娟 李果 陈战 许光武 谢超 张迪
Format Journal Article
LanguageEnglish
Published China Shanghai Institute of Endocrinology, Ruijin Hospital, Shanghai Second Medical University, Shanghai 200025, China 01.04.2003
Subjects
Online AccessGet full text
ISSN0366-6999
2542-5641

Cover

More Information
Summary:Objectives To obtain prokaryotic expressed IA-2 recombinant protein and to identify its immunological activity.Methods The complimentary DNA (cDNA) coding for the intracytoplasmic part of IA-2 (IA-2ic) was amplified from human fetal brain RNA, and was subcloned into the PinPoint Xa-1 T vector to construct recombinant expression plasmid, and was then expressed in E. coil JM109 cells as a fusion protein with a biotinylated peptide sequence at the aminoterminus. The biotinylated fusion protein was then purified by affinity chromatography and was subsequently dialyzed. Finally, its immunogenicity was evaluated by enzyme linked immunosorbent assay (ELISA).Results The purified IA-2ic fusion protein resolved on sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) as a single Coomassie brilliant blue stained band with a molecular weight of 59 kDa and its immunogenicity was confirmed by ELISA.Conclusions E. coil expressed IA-2ic fusion protein has immunological activity. It can be used for detection of IA-2 autoantibodies (IA-2A) and for further studies on type 1 diabetes in future.
Bibliography:11-2154/R
R587.1
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0366-6999
2542-5641